[Treatment of malignant hematological diseases with autologous peripheral blood stem cell transplantation]
Related Experiment Video
Updated: Oct 9, 2026
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Objective:
To observe the effectiveness of autologous peripheral blood stem cell transplantation(ABSCT) in the treatment of malignant hematologic diseases.
Methods:
Thirteen ABSCT and 15 autologous peripheral blood stem cells(ABSC) combining autologous bone marrow transplantation (ABMT) were performed for hematological malignancy patients.
Results:
In polyactin A mobilization group, the mononuclear cells(MNC) collected in each case were 3.58 +/- 2.12 x 10(8)/kg, and in G-CSF mobilization group 6.68 +/- 5.31 x 10(8)/kg. Twenty-one of the 28 transplanted cases achieved continuous complete remission(CCR). The medium CCR duration was 18(5-58) month. The 3 year disease-free survival rate was 68.7% and relapse rate was 22.3%.
Conclusion:
After ABSCT or ABSC combining ABMT, there were earlier hematopoietic reconstitution and fewer complications than that after ABMT.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
01:01Regulation of Hematopoietic Stem Cells